Evidence map›Paper›PMID 24400121›Full record

ArticlePloS one2014

miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions.

Eva Maria Pinatel, Francesca Orso, Elisa Penna, Daniela Cimino, Angela Rita Elia, Paola Circosta, Patrizia Dentelli, Maria Felice Brizzi, Paolo Provero, Daniela Taverna

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Tumor Suppressor microRNAs in Gastrointestinal Cancers: A Mini-Review.Recent advances in inflammation & allergy drug discovery · 2022
    Review
  9. Review
  10. MicroRNA Regulation of Breast Cancer Stemness.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Article
  13. Review
  14. The "Janus Face" of Platelets in Cancer.International journal of molecular sciences · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Eva Maria PinatelMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Francesca OrsoMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy ; Center for Molecular Systems Biology, University of Torino, Torino, Italy.
Elisa PennaMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Daniela CiminoMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy ; Center for Molecular Systems Biology, University of Torino, Torino, Italy.
Angela Rita EliaMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy.
Paola CircostaMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy.
Patrizia DentelliDepartment of Medical Sciences, University of Torino, Torino, Italy.
Maria Felice BrizziDepartment of Medical Sciences, University of Torino, Torino, Italy.
Paolo ProveroMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy ; Center for Translational Genomics and Bioinformatics, San Raffaele Scientific Institute, Milan, Italy.
Daniela TavernaMolecular Biotechnology Center (MBC), University of Torino, Torino, Italy ; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy ; Center for Molecular Systems Biology, University of Torino, Torino, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs are single-stranded non-coding RNAs that simultaneously down-modulate the expression of multiple genes post-transcriptionally by binding to the 3'UTRs of target mRNAs. Here we used computational methods to predict microRNAs relevant in breast cancer progression. Specifically, we applied different microRNA target prediction algorithms to various groups of differentially expressed protein-coding genes obtained from four breast cancer datasets. Six potential candidates were identified, among them miR-223, previously described to be highly expressed in the tumor microenvironment and known to be actively transferred into breast cancer cells. To investigate the function of miR-223 in tumorigenesis and to define its molecular mechanism, we overexpressed miR-223 in breast cancer cells in a transient or stable manner. Alternatively we overexpressed miR-223 in mouse embryonic fibroblasts or HEK293 cells and used their conditioned medium to treat tumor cells. With both approaches, we obtained elevated levels of miR-223 in tumor cells and observed decreased migration, increased cell death in anoikis conditions and augmented sensitivity to chemotherapy but no effect on adhesion and proliferation. The analysis of miR-223 predicted targets revealed enrichment in cell death and survival-related genes and in pathways frequently altered in breast cancer. Among these genes, we showed that protein levels for STAT5A, ITGA3 and NRAS were modulated by miR-223. In addition, we proved that STAT5A is a direct miR-223 target and highlighted a possible correlation between miR-223 and STAT5A in migration and chemotherapy response. Our investigation revealed that a computational analysis of cancer gene expression datasets can be a relevant tool to identify microRNAs involved in cancer progression and that miR-223 has a prominent role in breast malignancy that could potentially be exploited therapeutically.

Indexed as

3' Untranslated RegionsAnoikisAntineoplastic AgentsBase PairingBase SequenceBreast NeoplasmsCell DeathCell Line, TumorCell MovementComputational BiologyDatabases, FactualDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumans3' Untranslated RegionsAntineoplastic AgentsMicroRNAsMIR223, humanSTAT5 Transcription Factor

Identifiers

PMID24400121
PMCPMC3882278
OpenAlexW1986114891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.